Ming Bioventures Leads ~USD14m Series B for China’s Minimax Medical
Source(s): ChinaVenture
Ming Bioventures led a ~CNY100m (~USD14m) Series B for Minimax Medical, a China-based developer of minimally invasive medical devices, with participation from Cowin Capital and Addor Capital. Read more